Efficacy and Safety of Angiotensin Receptor-neprilysin   Inhibitor (ARNI) in Patients with Congestive Heart Failure

Aamir Javaid, Ahmad Salman, Muhammad Furrakh Maqbool, Liaqat Ali, Haroon Aziz Khan Babar, Abdul Rauf Aamir

Efficacy and Safety of Angiotensin Receptor-neprilysin Inhibitor (ARNI) in Patients with Congestive Heart Failure

Authors

Aamir Javaid, Ahmad Salman, Muhammad Furrakh Maqbool, Liaqat Ali, Haroon Aziz Khan Babar, Abdul Rauf Aamir

Keywords:

Chronic Heart Failure, ARNI, Sacubitril/Valsartan, Efficacy, Safety.

Abstract

Background: Angiotensin Receptor-Neprilysin Inhibitors (ARNI) have changed the landscape oftherapeutic options in chronic heart failure (CHF). Although efficacy is determined in trials, local practice requires real-world data in varying populations, such as Pakistan

References

1. Jariwala P, Punjani A, Boorugu H, Madhawar DBJIHJ. A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis. 2021;73(2):211-213.

Downloads

Published

2026-05-13

How to Cite

Aamir Javaid, Ahmad Salman, Muhammad Furrakh Maqbool, Liaqat Ali, Haroon Aziz Khan Babar, Abdul Rauf Aamir. (2026). Efficacy and Safety of Angiotensin Receptor-neprilysin Inhibitor (ARNI) in Patients with Congestive Heart Failure. International Journal of Pharmacy Research & Technology (IJPRT), 16(1), 2528–2533. Retrieved from https://ijprt.org/index.php/pub/article/view/1910